Fundamentals of molecular targeted therapy for primary central nervous system lymphoma based on genomic alterations

Fundamentals of molecular targeted therapy for primary central nervous system lymphoma based on genomic alterations - Genomic alterations in CNS lymphoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000003929

Enrollment

Registered

2010-07-21

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary central nervous system lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Brain tumor tissue obtained at stereotactic and craniotomy operation by skillful neurosurgeons. 2. Two parts of brain tumor tissue, one is for pathological diagnosis (formalin fixation) and another is for genomic analysis (frozen tissue). 3. Pathological diagnosis is primary CNS lymphoma

Exclusion criteria

Exclusion criteria: nothing particular

Design outcomes

Primary

Measure	Time frame
Identify primary CNS lymphoma specific genomic alterations. Among them, find molecular target for development and progression of lymphoma	—

Countries

Japan

Contacts

Public ContactShingo Takano

Faculty of Medicine, University of Tsukuba Department of Neurosurgery

shingo4@md.tsukuba.ac.jp029(853)3220

Outcome results